meta|Evidence - COVID-19
click on circles to display study description...
bromhexine (n=25) vs. control (n=25)
randomized controlled trial risk of bias NA
Bromhexine hydrochloride
Bromhexine hydrochloride 8 mg 3 times per day starting from the day before the first contact with COVID-19 (first day of work in an infection department).
Control
Without any placebo/additional drug prescribed.
COVID-19 prophylaxis (excluding children)
Participants over 18 years who were employed within the emergency departments where patients with confirmed/suspected COVID-19 were admitted, intensive care units, and clinical departments. All participants were obliged to wear personal protective equipment (PPE) as prescribed by WHO recommendations and local instructions. The PPE included respirators class FFP2 or FFP3, full skin covering, and protective eyeglasses.Participants were excluded if they had symptoms of respiratory infection within the last 2 months or a history of COVID-19, or a positive nasopharyngeal swab polymerase chain reaction (PCR) test to SARS-CoV-2 before the day of randomization, a confirmed direct contact to a subject positive for SARS-CoV-2 within the last 14 days or had a positive serologic test (either IgM or IgG).
Open-label.
Single center,
Follow-up phone calls and e-mail surveys on days 7, 14, 21, 28, and at week 8, nasopharyngeal swab SARS-CoV-2 PCR tests performed every 7 days. COVID-19–related symptoms were assessed based on the U.S. Council for State and Territorial Epidemiologists Criteria for confirmed cases (positive nasopharyngeal swab PCR test), probable cases (the presence of cough, shortness of breath, or difficult breathing, or the presence of two or more symptoms of fever, chills, rigors, myalgia, headache, sore throat, and new olfactory and taste disorders), and possible cases (the presence of one or more compatible symptoms, which could include diarrhea).
powered by vis.js Network